Limits...
Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M, Epoetin Alfa Study Gro - Br. J. Cancer (2002)

Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.

View Article: PubMed Central - PubMed

Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Show MeSH

Related in: MedlinePlus

Study schema.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376290&req=5

fig1: Study schema.

Mentions: Patients self-administered the three QoL questionnaires as a single packet a maximum of four times during the study: (1) pretreatment (at the time of randomisation to either epoetin alfa or placebo); (2) before the start of the second on-study chemotherapy cycle for patients on a cyclic chemotherapy regimen (or approximately week 4); (3) before the start of the fifth on-study chemotherapy cycle (or approximately week 16); and (4) at study completion (within 5 days of study completion or at the time of early withdrawal) (Figure 1Figure 1


Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield L, Gagnon D, Zagari M, Cella D, Bresnahan B, Littlewood TJ, McNulty P, Gorzegno G, Freund M, Epoetin Alfa Study Gro - Br. J. Cancer (2002)

Study schema.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376290&req=5

fig1: Study schema.
Mentions: Patients self-administered the three QoL questionnaires as a single packet a maximum of four times during the study: (1) pretreatment (at the time of randomisation to either epoetin alfa or placebo); (2) before the start of the second on-study chemotherapy cycle for patients on a cyclic chemotherapy regimen (or approximately week 4); (3) before the start of the fifth on-study chemotherapy cycle (or approximately week 16); and (4) at study completion (within 5 days of study completion or at the time of early withdrawal) (Figure 1Figure 1

Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.

View Article: PubMed Central - PubMed

Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Show MeSH
Related in: MedlinePlus